These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10538922)

  • 21. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 22. Innovation in biotechnology: current and future states.
    Woollett GR
    Clin Pharmacol Ther; 2012 Jan; 91(1):17-20. PubMed ID: 22179626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition.
    Evens RP
    AAPS J; 2016 Jan; 18(1):281-5. PubMed ID: 26475480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 26. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.
    Evens RP; Kaitin KI
    Clin Pharmacol Ther; 2014 May; 95(5):528-32. PubMed ID: 24448474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the pharmaceutical industry in drug development in dermatology.
    Cauwenbergh G
    Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 35. How Indian biotech is driving innovation.
    Nogrady B
    Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
    [No Abstract]   [Full Text] [Related]  

  • 36. Biosimilars advancements: Moving on to the future.
    Tsuruta LR; Lopes dos Santos M; Moro AM
    Biotechnol Prog; 2015; 31(5):1139-49. PubMed ID: 25708573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biotech pharmaceuticals and biotherapy: an overview.
    Steinberg FM; Raso J
    J Pharm Pharm Sci; 1998; 1(2):48-59. PubMed ID: 10945918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AchemAsia 2007 announcement: China's biotechnology industry on the upswing.
    Biotechnol J; 2007 Mar; 2(3):288-90. PubMed ID: 17354215
    [No Abstract]   [Full Text] [Related]  

  • 40. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.